In vivo study on the pharmacological interactions between a chinese herbal formula ELP and antiresorptive drugs to counteract osteoporosis

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Ko, Chun Hay ^a   Siu, Wing Sum ^a   Wong, Hing Lok ^a   Gao, Si ^a   Shum, Wai Ting ^a   Lau, Ching Po ^a   Cheng, Sau Wan ^a   Tam, Jacqueline Chor Wing ^a   Hung, Leung Kim ^a   Fung, Kwok Pui ^a   Lau, Clara Bik San ^a   Han, Quan Bin ^a,b   Leung, Ping Chung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; DEOXYPYRIDINOLINE; ELP EXTRACT; HERBACEOUS AGENT; RALOXIFENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITOMETRY; BONE STRENGTH; BONE STRUCTURE; CONTROLLED STUDY; CROSS LINKING; DRUG EFFICACY; FEMALE; FEMUR; IN VIVO STUDY; LOW DRUG DOSE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; TIBIA; URINARY EXCRETION; URINE LEVEL;

EID: 84870216968     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/203732     Document Type: Article

References (28)

1. Dennison E., Mohamed M. A., Cooper C., Epidemiology of osteoporosis. Rheumatic Disease Clinics of North America 2006 32 4 617 629 2-s2.0-34247104615 10.1016/j.rdc.2006.08.003 (Pubitemid 46590097)
2. Lim L. S., Hoeksema L. J., Sherin K., Screening for osteoporosis in the adult U.S. population. ACPM position statement on preventive practice. American Journal of Preventive Medicine 2009 36 4 366 375 2-s2.0-61649115205 10.1016/j.amepre.2009.01.013
3. Leslie W. D., Schousboe J. T., A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Current Osteoporosis Reports 2011 9 3 129 140 2-s2.0-79957929880 10.1007/s11914-011-0060-5
4. International Osteoporosis Foundation,. Epidemiology, http://www.iofbonehealth.org/epidemiology
5. Gullberg B., Johnell O., Kanis J. A., World-wide projections for hip fracture. Osteoporosis International 1997 7 5 407 413 2-s2.0-0030791669 10.1007/PL00004148 (Pubitemid 27443065)
6. Siris E. S., Selby P. L., Saag K. G., Borgström F., Herings R. M. C., Silverman S. L., Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. American Journal of Medicine 2009 122 2 S3 S13 2-s2.0-58949097888 10.1016/j.amjmed.2008.12.002
7. Pendrys D. G., Silverman S. L., Osteonecrosis of the jaws and bisphosphonates. Current Osteoporosis Reports 2008 6 1 31 38 2-s2.0-44849118220 10.1007/s11914-008-0006-8
8. Briot K., Trémollières F., Thomas T., Roux C., How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 2007 74 1 24 31 2-s2.0-33847041451 10.1016/j.jbspin.2006.05.011
9. Siu W. S., Wong H. L., Lau C. P., Theeffects of an antiosteoporosis herbal formula containing Epimedii Herba, Ligustri Lucidi Fructus and Psoraleae Fructus on density and structure of rat long bones under tail-suspension, and its mechanisms ofaction. Phytotherapy Research. In press 10.1002/ptr.4743
10. Sun Y., Lee S. M. Y., Wong Y. M., Ching P. L., Pang C. S., Qin L., Ping C. L., Fung K. P., Dosing effects of an antiosteoporosis herbal formula-a preclinical investigation using a rat model. Phytotherapy Research 2008 22 2 267 273 2-s2.0-40549141837 10.1002/ptr.2291 (Pubitemid 351363252)
11. Leung P. C., Cheng K. F., Chan Y. H., An innovative herbal product for the prevention of osteoporosis. Chinese Journal of Integrative Medicine 2011 17 10 744 749 2-s2.0-84858307559
12. Wong M. S., Mok S. K., Chen W. F., Lai W. P., Leung P. C., Wang X. L., Yao X. S., Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. British Journal of Pharmacology 2010 159 4 939 949 2-s2.0-77249175670 10.1111/j.1476-5381.2009.00593.x
13. Zhao J., Ohba S., Komiyama Y., Shinkai M., Chung U. I., Nagamune T., Icariin: a potential osteoinductive compound for bone tissue engineering. Tissue Engineering A 2010 16 1 233 243 2-s2.0-77049109253 10.1089/ten.tea.2009.0165
14. Ko C. H., Lau K. M., Choy W. Y., Leung P. C., Effects of tea catechins, epigallocatechin, gallocatechin, and gallocatechin gallate, on bone metabolism. Journal of Agricultural and Food Chemistry 2009 57 16 7293 7297 2-s2.0-70349210558 10.1021/jf901545u
15. Chinese Pharmacopeia Commission, Chinese Pharmacopeia Commission, Pharmacopoeia of the People's Republic of China 2010 Beijing, China Chinese Medical Science and Technology Press
16. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005 Rockville, Md, USA U.S. Food and Drug Administration
17. Guy J. A., Shea M., Peter C. P., Morrissey R., Hayes W. C., Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcified Tissue International 1993 53 4 283 288 2-s2.0-0027279616 (Pubitemid 23275192)
18. Black L. J., Sato M., Rowley E. R., Magee D. E., Bekele A., Williams D. C., Cullinan G. J., Bendele R., Kauffman R. F., Bensch W. R., Frolik C. A., Termine J. D., Bryant H. U., Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Journal of Clinical Investigation 1994 93 1 63 69 2-s2.0-0028167482 (Pubitemid 24030821)
19. Sato M., Kim J., Short L. L., Slemenda C. W., Bryant H. U., Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. Journal of Pharmacology and Experimental Therapeutics 1995 272 3 1252 1259 2-s2.0-0028951607
20. Anumula S., Wehrli S. L., Magland J., Wright A. C., Wehrli F. W., Ultra-short echo-time MRI detects changes in bone mineralization and water content in OVX rat bone in response to alendronate treatment. Bone 2010 46 5 1391 1399 2-s2.0-77951256738 10.1016/j.bone.2010.01.372
21. Inderjeeth C. A., Chan K., Kwan K., Lai M., Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. Journal of Bone and Mineral Metabolism 2012 30 5 493 503 10.1007/s00774-012-0349-1
22. Hopkins R. B., Goeree R., Pullenayegum E., Adachi J. D., Papaioannou A., Xie F., Thabane L., The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskeletal Disorders 2011 12, article 209 2-s2.0-80053344658 10.1186/1471-2474-12-209
23. Siu W. S., Qin L., Leung K. S., pQCT bone strength index may serve as a better predictor than bone mineral density for long bone breaking strength. Journal of Bone and Mineral Metabolism 2003 21 5 316 322 2-s2.0-0142182402 10.1007/s00774-003-0427-5 (Pubitemid 38017710)
24. Bradford P. G., Gerace K. V., Roland R. L., Chrzan B. G., Estrogen regulation of apoptosis in osteoblasts. Physiology and Behavior 2010 99 2 181 185 2-s2.0-72649098225 10.1016/j.physbeh.2009.04.025
25. Zallone A., Direct and indirect estrogen actions on osteoblasts and osteoclasts. Annals of the New York Academy of Sciences 2006 1068 1 173 179 2-s2.0-33744777162 10.1196/annals.1346.019 (Pubitemid 43824147)
26. Dominguez L. J., Di Bella G., Belvedere M., Barbagallo M., Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology 2011 12 5 397 408 2-s2.0-79959210350 10.1007/s10522-011-9344-5
27. Taranta A., Brama M., Teti A., De luca V., Scandurra R., Spera G., Agnusdei D., Termine J. D., Migliaccio S., The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002 30 2 368 376 2-s2.0-0036171788 10.1016/S8756-3282(01)00685-8 (Pubitemid 34150159)
28. Michael H., Härkönen P. L., Kangas L., Väänänen H. K., Hentunen T. A., Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. British Journal of Pharmacology 2007 151 3 384 395 2-s2.0-34249690772 10.1038/sj.bjp.0707232 (Pubitemid 46842673)